<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04713501</url>
  </required_header>
  <id_info>
    <org_study_id>CHA-IRB-1158/09/20</org_study_id>
    <nct_id>NCT04713501</nct_id>
  </id_info>
  <brief_title>Program for Alleviating and Resolving Trauma and Stress 1</brief_title>
  <acronym>PARTS1</acronym>
  <official_title>Program for Alleviating and Resolving Trauma and Stress Study (Stage 1 Pilot)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge Health Alliance</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation for Self Leadership</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge Health Alliance</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-arm pilot study (Phase 1) will test the preliminary efficacy of a virtually&#xD;
      delivered, live-online 16-week group model of Internal Family Systems (IFS) for individuals&#xD;
      with PTSD, called the PARTS program, on PTSD symptoms measured by Clinician-Administered PTSD&#xD;
      Scale (CAPS-5). In addition, feasibility, acceptability, and effects on self-report PTSD and&#xD;
      disturbances of self-organization (DSO) will be secondary outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a single-arm pilot study to test the preliminary efficacy of a&#xD;
      virtually delivered, live-online 16-week group model of Internal Family Systems (IFS) for&#xD;
      individuals with PTSD, called the PARTS program, on PTSD symptoms measured by&#xD;
      Clinician-Administered PTSD Scale (CAPS-5).&#xD;
&#xD;
      Secondary outcomes include feasibility and acceptability of the PARTS program measured by a&#xD;
      Credibility/Expectancy Questionnaire (CEQ) and Treatment Satisfaction Questionnaire.&#xD;
      Secondary clinical outcomes include the effects of the PARTS program on self-report PTSD and&#xD;
      disturbances of self-organization (DSO). Exploratory aims of the study are to investigate the&#xD;
      effects on emotion regulation (DERS), self-trauma fusion (iPRISM-trauma), disassociation&#xD;
      (MDI), depression (CAT-DI), self-compassion (SCS-SF), perceived stress (PSS), mindfulness&#xD;
      (TMS), and interception (MAIA-2). Additional exploratory outcomes include changes in outcome&#xD;
      variables among PTSD subjects with baseline DSO and those without DSO as defined by the&#xD;
      International Trauma Questionnaire (ITQ).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Actual">July 31, 2021</completion_date>
  <primary_completion_date type="Actual">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>PARTS is a live-online group program intended to alleviate and resolve symptoms of stress and PTSD for patients in a community health care system.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline CAPS-5 at 16 Weeks</measure>
    <time_frame>Week 16</time_frame>
    <description>The primary aim of this study is to examine the preliminary efficacy of a live-online version of the PARTS program on PTSD symptoms measured by reduction in CAPS-5 over 24 weeks. The CAPS-5 is a 30-item questionnaire administered by a trained interviewer and is considered the &quot;gold standard&quot; assessment for PTSD diagnosis and symptoms as defined by the DSM-5. This measure also assesses the duration of symptoms, impact of symptoms on aspects of the participant's life, and if the participant meets criteria for the dissociative subtype of PTSD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retention</measure>
    <time_frame>Week 16</time_frame>
    <description>A secondary aim is to evaluate feasibility by demonstrating at least 50% of participants are retained in the program at 16 weeks..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability as assessed by Satisfaction Survey</measure>
    <time_frame>Week 16</time_frame>
    <description>Participants will complete a satisfaction survey and rate their likeliness to recommend the program to a friend, on a five point Likert-type scale. An average greater than 3 out of 5 represents acceptability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Self-reported PTSD symptoms (PCL-5) at 16 Weeks</measure>
    <time_frame>Week 16</time_frame>
    <description>Participants will be sent a link to complete the PTSD Checklist for DSM-5 (PCL-5), which is a self-report measure with 20 items, which is designed to measure PTSD symptom severity over the past month as measured by the DSM-5, in combination with additional diagnostic tools.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Self-reported PTSD symptoms (CAT-PTSD) at 16 Weeks</measure>
    <time_frame>Week 16</time_frame>
    <description>Participants will be sent a link to complete the CAT-MH (Computer Adaptive Testing for Mental Health) interview on a computer, tablet or phone. This outcome refers to the CAT-PTSD severity score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Disturbances of Self Organization -- International Trauma Questionnaire (ITQ-DSO-9) at 16 Weeks</measure>
    <time_frame>Week 16</time_frame>
    <description>The International Trauma Questionnaire (ITQ) is the first instrument designed to capture the ICD-11 PTSD and Complex PTSD (CPTSD) diagnoses. The last 6 items measure DSO symptoms characteristic of ICD-11 CPTSD. Each set of items have 3 severity of impact on functioning questions. The ITQ-DSO-9 includes just the 6 DSO items with 3 severity questions. The ITQ-DSO-9 will be used monthly for self-report of changes in DSO symptoms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from Baseline Difficulties in Emotion Regulation (DERS) Scale at 16 Weeks</measure>
    <time_frame>Week 16</time_frame>
    <description>The DERS is a 36-item self-report scale designed to assess emotional dysregulation. The scale assess 6 aspects of emotional dysregulation: non-acceptance of emotional responses (&quot;When I'm upset, I become embarrassed for feeling that way&quot;), difficulties engaging in goal directed behavior (&quot;When I'm upset, I have difficulty thinking about anything else&quot;), impulse control difficulties (&quot;When I'm upset, I lose control over my behaviors&quot;), lack of emotional awareness (&quot;When I'm upset, I take time to figure out what I'm really feeling (reverse-scored)&quot;, limited access to emotion regulation strategies (&quot;When I'm upset, it takes me a long time to feel better&quot;), and lack of emotional clarity (&quot;I have no idea how I am feeling&quot;).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline Pictorial Representation of Illness and Self Measure (PRISM) --Trauma at 16 Weeks</measure>
    <time_frame>Week 16</time_frame>
    <description>The Pictorial Representation of Illness and Self Measure (PRISM) is a visual method to assess the global burden of illness, measuring the participant's &quot;self-trauma fusion&quot;. Using the iPrism Lite ipad app, the user places a disk representing the illness in relation to a disk representing the self.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline Multiscale Dissociation Inventory (MDI) at 16 Weeks</measure>
    <time_frame>Week 16</time_frame>
    <description>The MDI is a 30-item self-report inventory measuring frequency of dissociative symptoms (e.g., depersonalization, derealization, emotional constriction, identity dissociation, etc.)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline Depression (CAT-DI) at 16 Weeks</measure>
    <time_frame>Week 16</time_frame>
    <description>Participants will be sent a link to complete the CAT-MH (Computer Adaptive Testing for Mental Health) interview on a computer, tablet or phone. This outcome will assess depression severity with the CAT-DI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline Self-Compassion Scale (SCS-SF) at 16 Weeks</measure>
    <time_frame>Week 16</time_frame>
    <description>The SCS-SF is an abbreviated 12-item form of the original 26-item Self-Compassion Scale. This scale evaluates 6 different aspects of self-compassion: Self-Kindness (e.g., ''I try to be understanding and patient toward those aspects of my personality I don't like''), Self-Judgment (e.g., ''I'm disapproving and judgmental about my own flaws and inadequacies''), Common Humanity (e.g., ''I try to see my failings as part of the human condition''), Isolation (e.g., ''When I feel inadequate in some way, I try to remind myself that feelings of inadequacy are shared by most people&quot;), Mindfulness (e.g., ''When something painful happens I try to take a balanced view of the situation''), and Over-Identification (e.g., ''When I'm feeling down I tend to obsess and fixate on everything that's wrong.''). The scale is scored on a 5-point Likert scale (1 = Almost never; 5 = Almost always), and negative subscale items are reverse scored.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline Perceived Stress Scale (PSS-4) at 16 Weeks</measure>
    <time_frame>Week 16</time_frame>
    <description>The PSS-4 uses 4 items to measure the degree to which situations in life are stressful, evaluating how overloaded, unpredictable, and uncontrollable one finds one's life. Each item is scored on a 5-point Likert scale from 0 (Never) to 4 (Very often).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline Toronto Mindfulness Scale (TMS) at 16 Weeks</measure>
    <time_frame>Week 16</time_frame>
    <description>The TMS is a 13-item scale evaluating mindfulness factors of curiosity and decentering.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change from Baseline Multidimensional Assessment of Interoceptive Awareness (MAIA-2) at 16 Weeks</measure>
    <time_frame>Week 16</time_frame>
    <description>The MAIA-2 is a 37-item self-report scale designed to assess multiple aspects of interoception and interoceptive awareness (e.g., body trusting).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Post-traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>PARTS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The PARTS Program is a 16-week group intervention model, with 8 individual clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PARTS Program</intervention_name>
    <description>The PARTS Program is a 16-week group intervention model, with 8 individual clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.</description>
    <arm_group_label>PARTS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        To qualify for inclusion in this study, a prospective participant must:&#xD;
&#xD;
          1. Be 18-70 years of age for the duration of the study;&#xD;
&#xD;
          2. Able to bill insurance for group psychotherapy and individual psychotherapy at CHA;&#xD;
&#xD;
          3. Be a current patient of CHA primary care, behavioral health care or CHA MindWell;&#xD;
&#xD;
          4. Have a current diagnosis of PTSD OR a CAT-MH PTSD measure P-CAT&gt;58;&#xD;
&#xD;
          5. Have sufficient English fluency and literacy skills to understand the consent process,&#xD;
             procedures and questionnaires and have the ability to provide written informed&#xD;
             consent;&#xD;
&#xD;
          6. Have access to the internet and an electronic device with adequate data capacity; to&#xD;
             complete questionnaires online and attend online videoconference groups;&#xD;
&#xD;
          7. Must be available and willing to attend the scheduled online group sessions for 16&#xD;
             weeks; and&#xD;
&#xD;
          8. Must be available and willing to complete the online computerized assessments and&#xD;
             phone interviews.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Any and all of the following criteria will exclude a prospective participant from the&#xD;
        study:&#xD;
&#xD;
          1. Inability to complete an informed consent assessment AND/OR inability to complete&#xD;
             baseline study assessment procedures (due to cognitive deficit, non- proficiency in&#xD;
             English literacy, or for any other reason);&#xD;
&#xD;
          2. Current participation in another experimental research study;&#xD;
&#xD;
          3. Expected medical hospitalization in the next six months from enrollment period;&#xD;
&#xD;
          4. Expected incarceration in the next six months from enrollment period;&#xD;
&#xD;
          5. Individuals who are pregnant with a due date within 26 weeks after study consent;&#xD;
&#xD;
          6. Insufficient level of severity of PTSD symptoms: PTSD score of less than 33 on the&#xD;
             PTSD Checklist for DSM-V (PCL-5) at screening visit;&#xD;
&#xD;
          7. Inability to participate safely in the study intervention and without disrupting the&#xD;
             group (in the opinion of principal investigator OR meeting any of the following&#xD;
             criteria):&#xD;
&#xD;
               -  Past year history of a psychotic disorder or clinician confirmed active psychosis&#xD;
                  (Severe level of psychosis on PSY-S-CAT &gt; 60 will trigger the requirement of a&#xD;
                  clinical assessment prior to participation in the program)&#xD;
&#xD;
               -  Bipolar I disorder history or severe level of mania on CAT-M/HM (&gt;70)&#xD;
&#xD;
               -  Acute suicidality or self-injurious behavior&#xD;
&#xD;
               -  Severe depression, indicated by CAT-DI PHQ-9 equivalency score &gt;20&#xD;
&#xD;
               -  Acute homicidality with plan and/or intent;&#xD;
&#xD;
               -  Hospitalization for suicide attempt or self-harm within three months of the&#xD;
                  enrollment period;&#xD;
&#xD;
               -  Severe Borderline Personality Disorder or other severe personality disorder that&#xD;
                  may lead to disruptions within the group; and/or&#xD;
&#xD;
               -  Moderate or severe Substance Use Disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zev Schuman-Olivier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge Health Alliance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cambridge Health Alliance</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cloitre M, Shevlin M, Brewin CR, Bisson JI, Roberts NP, Maercker A, Karatzias T, Hyland P. The International Trauma Questionnaire: development of a self-report measure of ICD-11 PTSD and complex PTSD. Acta Psychiatr Scand. 2018 Dec;138(6):536-546. doi: 10.1111/acps.12956. Epub 2018 Sep 3.</citation>
    <PMID>30178492</PMID>
  </reference>
  <reference>
    <citation>Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, Keane TM, Marx BP. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess. 2018 Mar;30(3):383-395. doi: 10.1037/pas0000486. Epub 2017 May 11.</citation>
    <PMID>28493729</PMID>
  </reference>
  <reference>
    <citation>Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation. J Trauma Stress. 2015 Dec;28(6):489-98. doi: 10.1002/jts.22059. Epub 2015 Nov 25.</citation>
    <PMID>26606250</PMID>
  </reference>
  <reference>
    <citation>Eisen SV, Schultz MR, Ni P, Haley SM, Smith EG, Spiro A, Osei-Bonsu PE, Nordberg S, Jette AM. Development and Validation of a Computerized-Adaptive Test for PTSD (P-CAT). Psychiatr Serv. 2016 Oct 1;67(10):1116-1123. Epub 2016 Jun 1.</citation>
    <PMID>27247175</PMID>
  </reference>
  <reference>
    <citation>Wittmann L, Schnyder U, BÃ¼chi S. PRISM (Pictorial Representation of Illness and Self Measure): a new method for the assessment of suffering after trauma. J Trauma Stress. 2012 Feb;25(1):94-7. doi: 10.1002/jts.20710. Epub 2012 Jan 25.</citation>
    <PMID>22278709</PMID>
  </reference>
  <reference>
    <citation>Briere J, Weathers FW, Runtz M. Is dissociation a multidimensional construct? Data from the Multiscale Dissociation Inventory. J Trauma Stress. 2005 Jun;18(3):221-31.</citation>
    <PMID>16281216</PMID>
  </reference>
  <reference>
    <citation>Achtyes ED, Halstead S, Smart L, Moore T, Frank E, Kupfer DJ, Gibbons R. Validation of Computerized Adaptive Testing in an Outpatient Nonacademic Setting: The VOCATIONS Trial. Psychiatr Serv. 2015 Oct;66(10):1091-6. doi: 10.1176/appi.ps.201400390. Epub 2015 Jun 1.</citation>
    <PMID>26030317</PMID>
  </reference>
  <reference>
    <citation>Raes F, Pommier E, Neff KD, Van Gucht D. Construction and factorial validation of a short form of the Self-Compassion Scale. Clin Psychol Psychother. 2011 May-Jun;18(3):250-5. doi: 10.1002/cpp.702. Epub 2010 Jun 8.</citation>
    <PMID>21584907</PMID>
  </reference>
  <reference>
    <citation>Mitchell AM, Crane PA, Kim Y. Perceived stress in survivors of suicide: psychometric properties of the Perceived Stress Scale. Res Nurs Health. 2008 Dec;31(6):576-85. doi: 10.1002/nur.20284.</citation>
    <PMID>18449942</PMID>
  </reference>
  <reference>
    <citation>Lau MA, Bishop SR, Segal ZV, Buis T, Anderson ND, Carlson L, Shapiro S, Carmody J, Abbey S, Devins G. The Toronto Mindfulness Scale: development and validation. J Clin Psychol. 2006 Dec;62(12):1445-67.</citation>
    <PMID>17019673</PMID>
  </reference>
  <reference>
    <citation>Mehling WE, Acree M, Stewart A, Silas J, Jones A. The Multidimensional Assessment of Interoceptive Awareness, Version 2 (MAIA-2). PLoS One. 2018 Dec 4;13(12):e0208034. doi: 10.1371/journal.pone.0208034. eCollection 2018.</citation>
    <PMID>30513087</PMID>
  </reference>
  <reference>
    <citation>Gratz, K.L., Roemer, L. Multidimensional Assessment of Emotion Regulation and Dysregulation: Development, Factor Structure, and Initial Validation of the Difficulties in Emotion Regulation Scale. Journal of Psychopathology and Behavioral Assessment 26, 41-54 (2004). https://doi.org/10.1023/B:JOBA.0000007455.08539.94</citation>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge Health Alliance</investigator_affiliation>
    <investigator_full_name>Zev Schuman Olivier</investigator_full_name>
    <investigator_title>Assistant Professor, Psychiatry</investigator_title>
  </responsible_party>
  <keyword>PTSD; stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

